Sharon Tuckett, MD
Internal Medicine · Villa Rica, GANPI 1285607648
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $264,007 of the $264,672 with a category attached, or 99.7%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 92.7% of it on its own, with 17 other manufacturers making up the rest. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $1495.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$245K
- Shire North American Group Inc$19K
- AstraZeneca$119
- Novo Nordisk$105
- Boehringer Ingelheim$72
- Pfizer$49
- plus $279 from 12 others
What the payments were for
- Consulting fees$264,007100%
- Food & beverage$6650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 121 | $245,330 |
| Shire North American Group Inc | 17 | $18,719 |
| AstraZeneca | 8 | $119 |
| Novo Nordisk | 6 | $105 |
| Boehringer Ingelheim | 4 | $72 |
| Pfizer | 3 | $49 |
| Lilly USA, LLC | 3 | $41 |
| Astellas Pharma US Inc | 2 | $36 |
| AbbVie(2 entities) | 2 | $29 |
| Nalpropion Pharmaceuticals LLC | 2 | $29 |
| Johnson & Johnson | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $17 |
| Amgen | 1 | $16 |
| Novartis | 1 | $16 |
| Abbott | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$264,672 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 192 | $218,342 |
| MounjaroTirzepatide | 122 | $149,879 |
| TrulicityDulaglutide | 56 | $70,504 |
| EliquisApixaban | 70 | $51,776 |
| JardianceEmpagliflozin | 57 | $39,099 |
| CreonLipase/Protease/Amylase | 11 | $29,593 |
| JanuviaSitagliptin Phosphate | 41 | $28,852 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $25,197 |
| FarxigaDapagliflozin Propanediol | 24 | $21,007 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $17,951 |
| MyrbetriqMirabegron | 24 | $17,288 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,895 |
| GlyxambiEmpagliflozin/Linagliptin | 24 | $14,297 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $11,316 |
| GemtesaVibegron | 20 | $9,832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $41 | $220,383178 claims |
| Novo NordiskOzempic | $105 | $218,342192 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $72 | $60,89495 claims |
| PfizerEliquis | $49 | $51,77670 claims |
| AbbVieCreon, Synthroid | $29 | $36,842103 claims |
| MerckJanuvia | $12 | $28,85241 claims |
| AstraZenecaFarxiga | $119 | $21,00724 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $17,28824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Villa Rica
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
- Anna LedfordValdosta$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.